

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listing, of claims in the Application.

**Listing of Claims:**

1. (Currently amended) A method for treating Alzheimer's dementia in a patient in need thereof comprising administering to the patient a therapeutically effective amount of galantamine (I) and a statin (II) wherein the amount of galantamine (I) as base is 24 mg daily.
2. (Canceled)
3. (Original) The method of Claim 1 wherein the statin (II) is selected from the group comprising simvastatin, pravastatin, lovastatin, fluvastatin, atorvastatin or rosuvastatin, or a therapeutically active acid addition salt form of any of the foregoing, and galantamine (I) is in the form of galantamine hydrobromide (1:1) salt.
4. (Original) The method of Claim 1 wherein the amount of statin (II) is equal to or less than that which is approved in monotherapy with said statin (II).
5. (Canceled)
6. (Currently amended) A product containing as first active ingredient galantamine (I) and as second active ingredient a statin (II), as a combined preparation for simultaneous, separate or sequential use in the treatment of patients suffering from Alzheimer's dementia wherein the amount of galantamine (I) as base is 24 mg daily.
7. (Original) The product of claim 6 wherein the statin (II) is selected from the group comprising simvastatin, pravastatin, lovastatin, fluvastatin, atorvastatin or rosuvastatin, or a therapeutically active acid addition salt form of any of the foregoing, and galantamine (I) is in the form of galantamine hydrobromide (1:1) salt.
8. (Original) The product of claim 6 wherein the amount of statin (II) is equal to or less than that which is approved in monotherapy with said statin (II).
9. (Canceled)

10. (Original) A pharmaceutical composition comprising a carrier and as first active ingredient galantamine (I) and as second active ingredient a statin (II), each in an amount producing a therapeutic effect in patients suffering from dementia wherein the amount of galantamine (I) as base is 24 mg daily.
11. (Canceled)
12. (Original) The composition of claim 10 wherein the statin (I) is selected from the group comprising simvastatin, pravastatin, lovastatin, fluvastatin, atorvastatin or rosuvastatin, or a therapeutically active acid addition salt form of any of the foregoing, and galantamine is in the form of galantamine hydrobromide (1:1) salt.
13. (Original) The composition of claim 10 wherein the amount of statin (II) is equal to or less than that which is approved in monotherapy with said statin (II).
14. (Canceled)

Claims 15-18 (Canceled)

19. (Previously presented) A process for making a pharmaceutical composition as defined in claim 10 comprising mixing galantamine (I), a statin (II) and a pharmaceutically acceptable carrier.